A randomized controlled study on preoperative radiotherapy combined with surgery for centrally located hepatocellular carcinoma compared to surgical treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070833

Enrollment

Unknown

Registered

2023-04-24

Start date

2023-05-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

centrally located hepatocellular carcinoma

Interventions

Test group:Neoadjuvant radiotherapy+surgical treatment

Control group:surgery

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old, regardless of gender, voluntarily participate in this study; 2. Diagnosed as centrally located hepatocellular carcinoma and feasible for surgery; 3. Child Pugh A; 4. ECOG score of 0 or 1; 5. Possess follow-up ability.

Exclusion criteria

Exclusion criteria: 1. Simultaneously or previously suffering from other malignant tumors or distant metastasis before surgery; 2. Accept other forms of radiation therapy.

Design outcomes

Primary

Measure	Time frame
Disease free survival;Overall survival;	—

Secondary

Measure	Time frame
Safety;	—

Countries

China

Contacts

Public ContactWu Jianxiong

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

dr_wujx@163.com+86 15601170661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026